Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
If the FDA approves tirzepatide for a new indication that is not weight loss (for example, cardiovascular risk reduction, sleep apnea, or fatty liver disease), and that indication is not explicitly excluded by statute, TRICARE could cover tirzepatide for that indication
Some patients benefit from dose optimization or switching to PlexusDx's dual-compound GLP-Squared Injection (semaglutide + tirzepatide blend, at $289/mo month-to-month, or from $249/mo on the 6-month plan) if weight loss stalls despite compliance
Know where your nearest 24-hour pharmacy is
10.1016/j.phrs.2018.07.004 80
Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study
US$ 24.67
US$ 26.88
US$ 26.19
US$ 24.84
US$ 24.59
US$ 21.94
US$ 26.99
US$ 22.02
US$ 26.16
US$ 25.33
